Literature DB >> 10928584

Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease.

D M Maraganore1, M J Farrer, J A Hardy, S K McDonnell, D J Schaid, W A Rocca.   

Abstract

We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE). In a sample of 139 unrelated PD cases and 113 control subjects, the NAT2 M3 allele was associated with PD (odds ratio = 7.9; 95% confidence interval = 1.7-36.3). Case-control analyses for CYP2D6, APOE, and NAT2 M1 or M2 did not show a significant association. However, the age at onset of PD was significantly earlier in cases with the APOE epsilon2/epsilon3 genotype than in cases with the epsilon3/epsilon3 genotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928584     DOI: 10.1002/1531-8257(200007)15:4<714::aid-mds1018>3.0.co;2-3

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.

Authors:  M Martinez; A Brice; J R Vaughan; A Zimprich; M M B Breteler; G Meco; A Filla; M J Farrer; C Bétard; J Hardy; G De Michele; V Bonifati; B Oostra; T Gasser; N W Wood; A Dürr
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

2.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

3.  Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.

Authors:  Lisa F Potts; Alex C Cambon; Owen A Ross; Rosa Rademakers; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Shesh N Rai; Matthew J Farrer; David W Hein; Irene Litvan
Journal:  BMC Med Genet       Date:  2012-03-17       Impact factor: 2.103

4.  Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Authors:  Caroline H Williams-Gray; An Goris; Misuzu Saiki; Thomas Foltynie; D Alastair S Compston; Stephen J Sawcer; Roger A Barker
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

5.  N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.

Authors:  Juergen Borlak; Stella Marie Reamon-Buettner
Journal:  BMC Med Genet       Date:  2006-03-29       Impact factor: 2.103

Review 6.  Relationship between Apolipoprotein Superfamily and Parkinson's Disease.

Authors:  Lin Li; Ming-Su Liu; Guang-Qin Li; Jie Tang; Yan Liao; Yang Zheng; Tong-Li Guo; Xin Kang; Mao-Ting Yuan
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.